The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnimalcare Grp Regulatory News (ANCR)

Share Price Information for Animalcare Grp (ANCR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 236.00
Bid: 232.00
Ask: 240.00
Change: 0.00 (0.00%)
Spread: 8.00 (3.448%)
Open: 236.00
High: 240.00
Low: 236.00
Prev. Close: 236.00
ANCR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cortacare receives positive opinion from CVMP

9 Jul 2018 07:00

RNS Number : 9706T
Animalcare Group PLC
09 July 2018
 

 

09 July 2018

 

Animalcare Group plc

 

("Animalcare", the "Company" or the "Group")

 

Cortacare recommended for European marketing approval by CVMP

 

- Launch in European markets expected in Q4 2018

- Expands Animalcare's dermatology portfolio

 

Animalcare Group plc (AIM:ANCR), the pan-European animal health business, today announces that it has received a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), recommending European marketing authorisation for its dermatology product Cortacare. Animalcare plans to launch Cortacare in Q4 2018 through its direct sales operations in seven European countries and international distribution network.

Cortacare is a wholly-owned product, developed by Animalcare as a cutaneous spray for the treatment of inflammatory and pruritic dermatitis in dogs. The product is a corticosteroid designed to be applied topically to reduce inflammation and itching, which complements Animalcare's existing dermatology portfolio. Cortacare accumulates in the dog's skin, allowing for high local activity whilst minimising side effects, and leading to an improvement of skin lesions associated with the condition.

Chris Cardon, CEO of Animalcare Group plc, commented:

"As part of the reprioritisation of our product development pipeline we identified 17 core development products. We are pleased to see the first of these receive a positive recommendation from the CVMP, which paves the way for the commercialisation of this wholly owned product across Europe and expands our existing dermatology portfolio. Product development remains a key area for us and we are focused on building value within our development pipeline. We look forward to announcing further success as the pipeline progresses."

Enquiries:

 

Animalcare Group plc

Chris Cardon, Chief Executive Officer

Tel: 01904 487 687

Chris Brewster, Chief Financial Officer

Panmure Gordon (UK) Ltd (Nominated Adviser & Broker)

Tel: 020 7886 2500

Corporate Finance

Freddy Crossley / Peter Steel

Corporate Broking

James Stearns

Consilium Strategic Communications

Tel: 020 3709 5700

Amber Fennell

animalcare@consilium-comms.com

Chris Welsh

Olivia Manser

 

About Animalcare Group plc

Animalcare is a pan-European sales, marketing and product development company focused on the veterinary and animal health sectors. The Company has operations across Europe with direct sales in seven countries (UK, Belgium, Netherlands, Spain, Portugal, Italy and Germany), and exports to approximately 40 markets worldwide through global partnerships. The Company sells over 300 products including pharmaceuaticals, vaccines and nutraceuticals . Animalcare has a diverse pipeline of products in development and a strong network of distribution and in-license partnerships. For more information, please visit: www.animalcaregroup.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFVLLBVDFZBBX
Date   Source Headline
24th Dec 20087:00 amRNSStatement re share price movement
12th Dec 20082:48 pmRNSDirector/PDMR Shareholding
21st Nov 20083:47 pmRNSDirector/PDMR Shareholding
20th Nov 200812:25 pmRNSDirector/PDMR Shareholding
24th Oct 200810:32 amRNSDirector/PDMR Shareholding
23rd Oct 20083:58 pmRNSHolding(s) in Company
6th Oct 20083:52 pmRNSDirector/PDMR Shareholding
3rd Oct 20084:39 pmRNSDirector/PDMR Shareholding
2nd Oct 20089:04 amRNSDirector/PDMR Shareholding
30th Sep 20087:00 amRNSFinal Results
12th Aug 20088:46 amRNSHolding(s) in Company
10th Jul 20087:00 amRNSPre-Close Trading Statement
11th Apr 20084:58 pmRNSBoard appointment
31st Mar 20087:01 amRNSInterim Results
30th Jan 20083:43 pmRNSHolding(s) in Company
25th Jan 20085:04 pmRNSHolding(s) in Company
25th Jan 20085:03 pmRNSHolding(s) in Company
25th Jan 20085:02 pmRNSHolding(s) in Company
25th Jan 20085:01 pmRNSHolding(s) in Company
25th Jan 20085:00 pmRNSHolding(s) in Company
25th Jan 20084:59 pmRNSHolding(s) in Company
15th Jan 200811:07 amRNSChange of Name
15th Jan 20088:00 amRNSDisposal
15th Jan 20088:00 amRNS1st dealings on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.